Cristina de Min
Chief Medical Officer Topas Therapeutics
Cristina joined Topas in September 2021 and, as Chief Medical Officer, is responsible for all preclinical, translational, and clinical development programs. She spent 11 years at Roche in various executive positions, including Life Cycle Leader for the development of the IL-6 receptor antagonist tocilizumab (Actemra) for rheumatic diseases. She also served as Medical Director of Roche’s affiliate in Italy. Following Roche, she joined Novimmune, serving for nine years as Chief Medical Officer before the company was acquired by Swedish Orphan Biovitrum (SOBI). At Novimmune, she set up the clinical development department and was responsible for the global development strategy for drug candidates from translational activities through clinical development and registration. Cristina received her MD and board certification in endocrinology from the University of Milan.
Seminars
- Integration of biology with clinical trial design to evaluate antigen-specific tolerance induction, drawing on Phase I and II experience across celiac disease
- Endpoint selection guided by both mechanistic and clinical relevance, including strategies for incorporating non-invasive biomarkers and disease-appropriate readouts
- Analytical methods used to assess antigen-specific responses and evolving approaches to improve sensitivity and reliability
